
One of the two most common drugs used to treat age-related macular degeneration (AMD) appears better than the other, a new, small study suggests. Among 106 patients with “wet” age-related macular degeneration, 50% of those treated with aflibercept (Eylea) could be weaned off the drug after one year, compared with only 17% of those treated with bevacizumab (Avastin), researchers found. “The results from this study point to an additional, previously unappreciated advantage of aflibercept over bevacizumab,” said lead researcher Dr. Akrit Sodhi, an associate professor of ophthalmology at Johns Hopkins University School of Medicine in Baltimore. “The improved ability to wean patients off therapy will need to be considered when choosing between these two medications.” The findings suggest that aflibercept’s much higher price tag — it costs about $2,000 per treatment while bevacizumab costs only $100 per treatment — might be worth it. The study was funded by the U.S. National Eye Institute. AMD is the most common cause of vision loss among people 50 and older, affecting more than 7 million Americans. Of these, nearly 2 million who suffer from advanced AMD will lose their vision, the researchers noted. These patients include those who have wet AMD, which is characterized by the growth of abnormal blood vessels in the retina that can bleed or leak damaging fluids into light-sensing tissue. Treatment of wet AMD… read on > read on >